Helius Medical Technologies, Inc. to Present at Three Upcoming Investor Conferences in September
August 31 2020 - 2:00PM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced that management will participate in the
following upcoming investor conferences in September:
The LD 500 Virtual Investor Conference, which is being
held from September 1st-4th.
- Management will present on Tuesday, September 1st at 1:20 p.m.
Eastern Time.
The Wall Street Investor Forum Virtual
Conference, which is being held on September 10th.
- Management will present on Thursday, September 10th at 9:20
a.m. Eastern Time. The presentation will be followed by a virtual
breakout session.
The H.C. Wainwright 22nd Annual Global Investment
Conference, which is being held virtually from September
14th-16th.
- Management will present on Wednesday, September 16th at 12:00
p.m. Eastern Time.
Live audio webcasts of the presentations will be
provided under the ‘Events’ section of the Helius Medical
Technologies investor relations website at
https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.
Archives of the webcasts will be available for replay following the
conference.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s purpose is
to develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS™). For more information, visit
www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™)
is authorized for sale in Canada as a class II, non-implantable,
medical device intended as a short term treatment (14 weeks) of
gait deficit due to mild and moderate symptoms from multiple
sclerosis (MS), and chronic balance deficit due to mild-to-moderate
traumatic brain injury (mmTBI) and is to be used in conjunction
with physical therapy. The PoNS™ is an investigational medical
device in the United States, the European Union (“EU”), and
Australia (“AUS”). The device is currently under review for
clearance by the FDA. It is also under premarket review by the AUS
Therapeutic Goods Administration. PoNS™ is currently not
commercially available in the United States, the European Union or
Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.Mike Piccinino, CFAinvestorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024